Lotte Chilsung Beverage (005300) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
22 Jun, 2026Executive summary
Consolidated Q1 2026 sales rose 4.6% year-over-year to 9,525 billion KRW, with operating profit up 91.0% to 478 billion KRW and net profit up 366.6% to 253 billion KRW.
Beverage segment contributed 78.2% of sales and 63% of operating profit; liquor segment contributed 21.8% of sales and 37% of operating profit.
Continued expansion in zero-calorie and health-oriented beverages, and strong performance in soju and beer, including new product launches.
Overseas subsidiaries, especially in the Philippines, showed robust growth, with PCPPI posting KRW 258.9 billion in Q1 sales.
Operating margin improved from 2.7% to 5.0% year-over-year.
Financial highlights
Gross profit increased 9.0% year-over-year, reaching 3,216 billion KRW.
Profit before income tax surged 219.0% year-over-year to 342 billion KRW.
Debt to equity ratio improved to 165.1% from 167.7% at year-end 2025.
Basic EPS for ordinary shares was KRW 2,423, compared to KRW 697 in the prior year.
Cash and cash equivalents at period end were KRW 135.2 billion.
Outlook and guidance
2026 consolidated sales guidance is 41,000 billion KRW (+3.2% YoY), with operating profit targeted at 2,000 billion KRW (+19.6% YoY).
Focus on expanding new product sales, zero-calorie and functional beverage portfolios, profitability improvement, and scenario-based risk management for geopolitical uncertainties.
Continued investment in overseas markets, especially in Russia, China, and the US, to drive export growth.
Ongoing cost management and efficiency initiatives to support profitability.
Latest events from Lotte Chilsung Beverage
- Q2 sales up 38.1% YoY, but net profit and margins fell as overseas drove growth.005300
Q2 202423 Jun 2026 - Sales and profits fell, but zero-calorie and health products drove segment growth.005300
Q3 202423 Jun 2026 - Q1 2025 revenue and profit declined, with rising debt ratio and segment performance shifts.005300
Q1 202523 Jun 2026 - Profit growth in Q2 2025 driven by overseas and zero-calorie products, with strong full-year outlook.005300
Q2 202523 Jun 2026 - Profits and margins rose in Q3 2025, with overseas and health-focused products driving growth.005300
Q3 202523 Jun 2026 - Domestic sales and profits fell in Q4 2025, but overseas growth and 2026 recovery are forecast.005300
Q4 20251 Apr 2026 - Record sales in 2024 offset by profit decline; 2025 targets strong growth and margin recovery.005300
Q4 20245 Jun 2025